Advanced search
Publication Cover
Acta Cardiologica Volume 77, 2022 - Issue 8
Submit an article Journal homepage
508
Views
8
CrossRef citations to date
0
Altmetric
Review Articles

Cardiac amyloidosis: a review of the literature

Nils de Marneffea Department of Cardiology, University Hospital of Liege, Liege, BelgiumCorrespondence[email protected]
,
R. Dulgherub Head of Clinic, Department of Cardiology, University Hospital of Liege, Liege, Belgium
,
A. Ancionb Head of Clinic, Department of Cardiology, University Hospital of Liege, Liege, Belgium
,
M. Moonenb Head of Clinic, Department of Cardiology, University Hospital of Liege, Liege, Belgium
&
P. Lancellottic Professor at the University of Liege, Head of the Cardiology Department, Director of the Cardiovascular GIGA, University Hospital of Liege
Pages 683-692 | Received 28 Jun 2021, Accepted 05 Oct 2021, Published online: 19 Jul 2022

References

  • Alkhawam H, Patel D, Nguyen J, et al. Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options. Acta Cardiol. 2017;72(4):380–389.
  • Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404.
  • Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy. JAMA. 2020;324(1):79–89.
  • Falk RH, Alexander KM, Liao R, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323–1341. MDMDPHD MD, MPH
  • Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;73(22):2872–2891.
  • McWilliams-Koeppen HP, Foster JS, Hackenbrack N, et al. Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes. PLoS One. 2015;10(9):e0137716.
  • Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–2466.
  • Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–1300.
  • González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38(24):1895–1904.
  • Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med. 2008;263(3):294–301.
  • Habib G, Bucciarelli-Ducci C, Caforio ALP, et al. Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document in collaboration with the “working group on myocardial and pericardial diseases” of the european society of cardiology endorsed by the Indian academy of echocardiography. Eur Heart J Cardiovasc Imaging. 2017;18(10):1090–1121.
  • Ogawa H, Mizuno Y, Ohkawara S, et al. Cardiac amyloidosis presenting as microvascular angina. Angiology. 2001;52(4):273–278.
  • Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–1212.
  • Falk RH, Quarta CC. Echocardiography in cardiac amyloidosis. Heart Fail Rev. 2015;20(2):125–131.
  • Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis CLINICAL PERSPECTIVE. Circulation. 2015;132(16):1570–1579.
  • Dungu JN, Valencia O, Pinney JH, et al. CMR-Based differentiation of AL and ATTR cardiac amyloidosis. JACC: Cardiovascular Imaging. 2014;7(2):133–142.
  • Fontana M, Chung R, Hawkins PN, et al. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015;20(2):133–144.
  • Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis CLINICAL PERSPECTIVE. Circulation. 2016;133(24):2404–2412.
  • Dorbala S, Bokhari S, Miller E, et al. ASNC Practice points: 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. Released February 27 ; 2019.
  • Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. Cardiovascul Imag. 2011;4(6):659–670.
  • Ramaekers J, Janssens J, Waumans L, et al. Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience. Acta Cardiologica. 2020;75(2):138–146.
  • Ritts AJ, Cornell RF, Swiger K, et al. Current concepts of cardiac amyloidosis. Heart Fail Clin. 2017;13(2):409–416.
  • Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatmentCleveland. Cleve Clin J Med. 2017;84(12 suppl 3):12–26.
  • Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63(6):1285–1288.
  • Tan NY, Mohsin Y, Hodge DO, et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2016;27(10):1167–1173.
  • Itzhaki Ben Zadok O, Kornowski R. Cardiac care of patients with cardiac amyloidosis. Acta Haematol. 2020;143(4):343–349.
  • Donnellan E, Wazni O, Saliba W, et al. Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation and mortality. J Cardiovasc Electrophysiol. 2019;30(11):2427–2432.
  • Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2015;36(41):2793–2867. euv319.
  • Jimenez-Zepeda VH, Duggan P, Neri P, et al. Bortezomib-containing regimens for the treatment of newly diagnosed and relapsed amyloid light chain amyloidosis: a single-center experience. Clin Lymphoma Myeloma Leuk. 2016;16(6):e79–e84.
  • Sousa M, Monohan G, Rajagopalan N, et al. Heart transplantation in cardiac amyloidosis. Heart Fail Rev. 2017;22(3):317–327.
  • Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
  • Solomon SD, Adams D, Kristen A, et al. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary Transthyretin-Mediated amyloidosis. Circulation. 2019;139(4):431–443.
  • Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19(sup1):34–36.
  • Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012;101(10):805–813.
  • Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
  • Thibaud D, Pablo Garcia P, Mazen H, et al. Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2020;23(2):277–285.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.